Antibodies specifically directed to a soluble form of CTLA-4

Frank James Ward (Inventor), Robert Norman Barker (Inventor), Lekh Nath Dahal (Inventor)

Research output: Patent

44 Downloads (Pure)


The invention provides materials and methods relating to antibodies specific for a soluble form of CTLA-4 (sCLTA-4). Such antibodies have been shown to have a strong boosting effect on antigen-specific human immune responses.
Original languageEnglish
Patent numberUS8697845 B2
Priority date15/04/14
Publication statusPublished - 2 Sept 2010

Bibliographical note

New antibody molecule that binds specifically to soluble form of cytotoxic T-lymphocyte antigen, useful as vaccine e.g. to enhance antigen specific immune response against pathogens e.g. bacteria, virus e.g. HIV, and nematode

Patent Number(s): WO2010097597-A1 Original ; AU2010217453-A1 ; EP2401035-A1 Original ; CN102421482-A ; US2012107320-A1 Original ; CA2772648-A1 ; JP2012518425-W ; IN201106831-P4 ; US8697845-B2 Original ; JP5864266-B2 ; CN102421482-B ; AU2010217453-B2 ; EP2401035-B1 Original ; ES2662652-T3


Dive into the research topics of 'Antibodies specifically directed to a soluble form of CTLA-4'. Together they form a unique fingerprint.

Cite this